C3 and paroxysmal nocturnal hemoglobinuria: Nevertheless, like anti-C5 blockade, C3-blocking therapies carry a significant risk of serious infections, which supports the potential of local cell membrane C3d-targeted complement inhibitors as a safer alternative therapeutic approach for PNH patients who do not respond adequately to anti-C5 therapies.